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Background: Brain microvascular endothelial cells (BMVECs) constitute the primary limitation for passage of ions
and molecules from the blood into the brain through the blood brain barrier. Numerous multi-step procedures for
isolating and culturing BMVECs have been described. However, each one demonstrates major limitations in purity
of culture and/or low proliferation rate. Our goal was to study the efficiency of our pending patent medium,
Endothelial Proliferation Medium (EndoPM), on the isolation and purification of human and murine BMVECs.
Methods: BMVECs, cultured in EndoPM were compared to those cultured in a commercial medium EBM. Cultures
were characterized by flow cytometric analysis, lineage differentiation, the ability to form tube-like structure,
immunofluorescence, molecular analyses and also in an in vivo model assay. Moreover permeability was assayed by
monitoring the passage of Dextran-FITC through a tight monolayer of BMVECs grown to confluence in Boyden
chambers. One way Anova two-tailed test was utilized for all statistical analyses.
Results: The properties of ECs in human and murine BMVECs is confirmed by the expression of endothelial markers
(CD31, CD105, CD146, Tie-2 and vWF), of representative proangiogenic genes (ICAM1, VCAM1 and integrin ITGAV),
of considerable tube-forming ability, with low-density lipoprotein uptake, eNOS and GLUT-1 expression.
Furthermore cells are able to express markers of the junctional architecture as VE-cadherin, β-catenin and Claudin-5
and greatly reduce dextran permeability as barrier functional test. Moreover BMVECs spontaneously organize in
vascular-like structures and maintain the expression of endothelial markers in an in vivo xenograft model assay. The
significant effect of EndoPM is confirmed by the study of proliferation index, survival index and the behaviour of
BMVECs and fibroblasts in co-culture conditions.
Conclusion: Herein we describe a simple and reproducible method for the isolation and expansion of human and
mouse BMVECs, based on a newly formulated medium (EndoPM) with optimized concentration of growth factors
(EGF, FGF-2 and Bovine Brain Extract-BBE). This procedure should facilitate the isolation and expansion of human
and mouse BMVECs with extended lifetime, good viability and purity. This approach may provide an effective
strategy to aid phenotypical and functional studies of brain vessels under physiological and pathological conditions.
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Angiogenesis is a hallmark of diverse pathologies, such
as cancer, atherosclerosis and cerebrovascular diseases
[1,2]. The progression of all these diseases depends also
on the formation of new blood vessels; hence, there is
substantial interest in the specific features of endothelial
cells (ECs) during the development of these pathologies.
The growing evidence that abnormal ECs frequently
accompany organ dysfunction and disease [3,4], has led
to a strong interest in the development of model systems
both in vivo and in vitro to study EC characteristics. ECs
comprise only 1–2% of the total number of cells in
tissues [2], therefore methods for their purification and
subsequent characterization are highly desirable.
Brain microvascular endothelial cells (BMVECs) form
the major element of the blood-brain barrier (BBB) and
constitute the primary limitation for passage of sub-
stances, both soluble and cellular, from the blood into
the brain [5]. They possess unique morphological and
functional characteristics that distinguish them from
organs- and tissue-endothelium [6]. To perform their
physiological function, BMVECs utilize unique features
such as specialized tight junctions and various trans-
porters for vitamins, nutrients and metabolic precursors,
helping to maintain brain homeostasis [7].
Various multi-step procedures for isolating and cultur-
ing BMVECs derived from different species [8] are avail-
able, with both advantages and limitations [9,10].
While primary BMVECs cultures retain the closest
similarity to phenotypic characteristics of brain endothe-
lium [11], they are extremely time consuming and
expensive to generate, and are easily contaminated by
other cells. They are difficult to obtain in large numbers,
with a good proliferation and viability and free from
fibroblasts contamination [12-14].
While immortalized brain EC lines offer a number of
investigative advantages, including less time required for
their isolation and in vitro growth, immortalization
involves the introduction of foreign, immortalizing genes
(i.e. telomerase and SV40) that may affect a great variety
of cellular functions as they may interact with numerous
proteins and alter the physiological cell cycle as well as
the expression of several proteins and receptors [15].
Here, we describe a new procedure to isolate and cul-
tivate human and murine BMVECs utilizing our pending
patent medium, the Endothelial Proliferation Medium
called EndoPM (patent number MI2011A 000201) that
allows for human and mouse BMVECs isolation and a
longer proliferation, particularly when compared with
BMVECs cultured in standard commercial available
Endothelial Basal Medium (EBM) with growth factors
supplement kit. EndoPM is a blend of essential amino
acids, inorganic salts and other components, along with
an optimized mix of human growth factors where EGFand FGF-2 are at high concentration levels. We demon-
strate that BMVECs cultured in EndoPM retain their
morphological and functional key characteristics of
in vivo ECs [16]. Furthermore cells cultured in EndoPM
medium are able to express functional markers of tight
junction as Claudin-5, as well as adherent junction
proteins such as β-catenin and VE-cadherin and greatly
reduce dextran permeability as barrier functional test.
In conclusion, our optimized medium supports the
culture of established human and mouse BMVECs and
improves the efficacy of their isolation and expansion
in vitro allowing the study of physiological and patho-
physiological endothelium.
Methods
Isolation of BMVECs
The experimental protocol was approved by the ethics
committee of the IRCCS Foundation Neurological
Institute “C. Besta” (Milan, Italy) and IRCCS Foundation
Ospedale Maggiore Policlinico, Mangiagalli and Regina
Elena (Milan, Italy). Human fetal brains were obtained
from five 10-12 week-old healthy foetuses, according to
the ethical guidelines of the European Network for
Transplantation (NECTAR). Tissue specimens were
stored in medium DMEM/F12 (Gibco, Grand Island,
NY) containing, penicillin 100 U/ml at 4°C for less than
48 h prior to processing.
Procedures involving animals and their care were
conducted in conformity with all procedures following
institutional guidelines which, in turn, are in compliance
with national (D.L. No. 116, G.U. Suppl. 40, Feb. 18, 1992,
Circolare No. 8, G.U., 14 Luglio 1994) and international
laws and policies (EEC Council Directive 86/609, OJ L
358, 1 Dec.12, 1987; NIH Guide for the Care and use of
Laboratory Animals, U.S. National Research Council,
1996). Brains from male CD1 mice (Charles River, Calco,
LC, Italy) were removed and stored in DMEM/F12 plus
antibiotics until used. After several washes with PBS/anti-
biotics, tissues were finely minced using surgical scissors
and then incubated with Liberase Blendzyme 2 (Roche,
Mannheim, Germany) at a concentration of 0.625 Wu/ml
at 37°C on a rotator for 2 hours. After enzymatic
digestion, the cell suspension was washed with D-PBS,
centrifuged at 1200 rpm/10 min and then plated in
25 cm2-flask (one for each brain) coated with collagen
type I (BD Bioscience, San Diego, CA, USA), in EndoPM,
specifically developed by our laboratory (pending patent
medium MI2011A 000201) to select and expand ECs. This
medium contains very high levels of growth factors
(Bovine Brain Extract (6 μg/mL), Fibroblast Growth Factor
(5 ng/mL), and Epidermal Growth Factor (10 ng/mL) in
particular) and a blend of hormones called Hormone
Mix, composed by by apotransferrin (48.82 μg/mL), sele-
nium (2.37 ng/mL), progesterone (2.88 ng/mL), putrescine
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tained at 37°C, 5% CO2. After 24 h of culture, non adher-
ent cells were removed from the flasks and reseeded in a
new collagen type I -coated culture 25 cm2-flask in 6 mL
of fresh EndoPM medium.
The medium was changed every 10 days, the cultured
cells were passaged at a split ratio of 1:4 every 14 days
and detached by TrypLE Select (Gibco). BMVECs at
passages P10-P15 were used as indicated for all experi-
ments. Experiments were performed in triplicates.
Human and Mouse Microvascular Endothelial Cells
(HMVECs), cultured in complete EBM medium with
growth factors supplement kit (Lonza Group Ltd, Basel
Switzerland), were utilized as control samples.
Survival assay
All experiments were done on 12-well plates, in tripli-
cate for each treatment. Cells were dissociated with
TrypLE (Gibco) and diluted to 5 × 105 cells/mL. 5 × 105
cells were added into each well and placed into 5% CO2,
37°C incubator. EndoPM or EBM were added to the
specified well. At different time points, cells were dis-
sociated with TrypLE and counted by cytometry. For
proliferation experiments, media were changed weekly
until the day of analysis.
Proliferation index represents the cell number at a
specific time point divided by the number of input cells
at time 0; survival index represents the number of
harvested live cells 12 hours after plating in EndoPM or
EBM (Table 1).
Nutrient starvation
Human and mouse BMVECs were incubated in growth
media at 37°C 5% CO2 in a humidified atmosphere, in a
6-wells culture plate, 3 × 105 cells per well. When 80%
confluence was reached, cells were washed twice in PBS
and incubated overnight in starvation medium com-
posed of DMEM/F12 (Gibco), 1% L-Glutamine (Gibco),
0.5% FBS, to induce cells synchronization.
The day after, starved cells were treated with complete
EndoPM or EBM medium for 5h or overnight. Cells were
than detached with TripLE (Gibco) following manufac-
turer instruction and processed for cell cycle analysis.
Cell cycle analysis
Cell cycle was evaluated by flow cytomety analysis after
synchronization in starvation medium. After the syn-Table 1 Proliferation index and survival index of human and
Human
EndoPM
proliferation index 1087,77 ± 105 422,
survival index 102,05 ± 3,04 36,8chronization time, starved cells were treated with
complete EndoPM or EBM medium for 5 h or overnight.
5 × 105 human or mouse BMVECs cells were fixed in
1 ml cold ethanol (70% vol/vol in PBS) with gentle
vortexing (about 5 s) to obtain a mono-dispersed cell
suspension, and maintained in ethanol, at 4°C, for at
least 2 h. After ethanol fixation, cells were centrifuge
1200 rpm/10 min and the ethanol thoroughly decanted.
The pellet was then re-suspended in 500 μL of PBS and in-
cubated with 1 mg/mL RNAse A, at 37°C for 15 minutes.
Cells were centrifuge for 1200 rpm /10 min and the
supernatant discarded. The pellet was then resuspended
in 500 μL of PBS with the addition of 50 μg/mL of
Propidium iodide (PI) staining solution. Cells were kept in
the dark at 37°C for 20 min and then analysed using a
FACScalibur flow cytometer and Cell Quest software
(BD Bioscience).
Co-culture of human BMVECs and fibroblasts (NHDF)
Human BMVECs were cultured in EndoPM or EBM in
standard conditions. Normal human dermal fibroblasts
(NHDF, Promocell GmbH, Heidelberg, Germany) were
cultured in MEM Eagle Medium (Lonza) supplemented
with 10% FBS and 1% L-Glutamine. Co-cultures (n = 3)
were produced by pooling BMVECS and NHDF with a
defined ratio (BMVECS:NHDF = 3:1) in the follo-
wing medium mix (EndoPM: EMEM medium = 4:1).
Fibroblasts were previously labeled with CFDA-SE
(Invitrogen, Carlsbad, CA, USA) to permit their identi-
fication in co-culture systems. The data were acquired
by immunofluorescence.
Fibroblast quantification: The quantification of CFDA-
SE positive cells was performed by fluorescence micros-
copy at T0, T7 and T14 (days in culture). Briefly, cells
counts were performed on a minimum of 9 independent
fields (3 fields/3 coverslips/treatment) of photomicro-
graphs captured with the 40× objective. Total counts of
CFDA-SE positive cells were performed and the number
of positive cells per culture was expressed as the
percentage of the total cells. DAPI supplied the total
number of cells. Images were acquired by a Nikon
Eclipse TE300 inverted microscope equipped with a
Zeiss Axiovision device camera.
Immunofluorescence and flow cytometry
Human and murine BMVECs were plated on collagen-
coated permanox chamber slides (Nunc, Naperville, IL,mouse BMVECs cultured in EndoPM or EBM
Mouse
EBM EndoPM EBM
96 ± 40,13 666 ± 53,2 372,22 ± 35,3
5 ± 12,03 98,53 ± 4,13 49,15 ± 10,2
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endothelial markers by means of immunostainings as
previously described [17]. VE-Cadherin, Claudin-5 and
β-catenin were detected, according to manufacturer
instructions, 5 days after incubations of cells in EndoPM
medium without Hormone Mix.
Three separate immunofluorescence analyses were
performed on human and murine BMVECs; positive
cells were counted in a blind manner.
Human and murine BMVECs were characterized for
endothelial marker expression also by means of FACS.
The controls were isotype-matched mouse IgG. The
cytometric analyses were done with a FACScalibur flow
cytometer and Cell Quest software (BD Bioscience). The
antibodies used for immunofluorescence and flow cyto-
metry are described in Table 2.Table 2 Human and mouse antibodies utilized for
immunofluorescence and flow cytometry analyses
Antibody Dilution Manufacturer
Immunofluorescence
Human
CD31 1:50 Sigma
vWF 1:50 Sigma
GLUT-1 1:100 Millipore
e-NOS 1:100 Millipore
UEA-1 1:20 Sigma
hNAg 1:20 Chemicon
Draq 5 1:800 Alexis
VE-cadherin 1:250 Santa Cruz
Claudin-5 1:1000 Invitrogen
β-catenin 1:250 Abcam
Mouse
CD31 1:100 Millipore
vWF 1:50 Santa Cruz Biotechnology
GLUT-1 1:100 Millipore
e-NOS 1:100 Millipore
Flow cytometry
Human
CD31-PE (AC128) 1:40 Miltenyi
CD105-FITC ( SN6) 1:40 Serotec
CD146-PE ( F4-35H7) 1:20 Biocytex
UEA-1-FITC 1:50 Sigma
Mouse
CD31-PE (MEC13.3) 1:20 BD Biosciences
CD34-FITC (RAM34) 1:20 BD Biosciences
CD146-FITC (P1H12) 1:20 Chemicon
Tie-2-PE (1E11DH) 1:50 MilliporeCord formation on Matrigel
200 μL of Matrigel (12.5 mg/mL, BD Bioscience) at 4°C
were transferred to pre-chilled 24-wells culture plates.
After gentle agitation to ensure complete coating, plates
were incubated for 30 minutes at 37°C to allow the solidi-
fication of Matrigel. Human and murine BMVECs were
then seeded at a concentration of 6 × 104/well in EndoPM
[18]. Cord formation was detectable after 5-7 hours of
incubation in ten fields randomly photographed.
Acetylated low-density lipoprotein uptake
To determine the uptake of Dil labeled acetylated low-
density lipoprotein, cells were incubated with 10 mg/mL
Dil-Ac-LDL (Molecular Probes, Invitrogen) at 37°C for 4
hours. The cells were washed with PBS and mounted with
Fluorsave™ (Calbiochem-Millipore, Temecula, CA, USA).
The slides were analyzed using a Nikon Eclipse TE300
inverted microscope equipped with a Zeiss Axiovision de-
vice camera.
Vascular permeability assay
2 × 104 BMVECs were plated on collagen coated insert of
Transwell (Corning Life Science, Union City, CA, USA)
with membrane filter (0.4-μm pore size) in EndoPM
medium in the upper and in the lower chamber. 5 days
before assay the cells were grown in EndoPM medium
without Hormone Mix, until they have reached confluence
(day 3 = semiconfluence). The confluence was determined
by hematoxylin-eosin staining of sentinel well. FITC-
dextran (4 μL, 25 mg/mL initial concentration) (Sigma-Al-
drich, St.Louis, MO, USA) was filled to the insert. Every 30
min, 50 μL of medium was collected from the lower cham-
ber. The aliquots were diluted to 1 mL with 1× PBS. 100
μL of each diluted sample were transferred into 96-well
black plates and the fluorescent content at 492/520 nm ab-
sorption/emission wavelengths for FITC-dextran was
measured.
Transfer permeability of the EC monolayer correlates
with the fluorescent intensity in the lower chamber. No
fluorescent intensity is detected in the lower chamber
once the EC monolayer reaches confluency [19].
Detection of endothelial-specific gene transcripts by
qualitative PCR and quantitative real time PCR
After 60 DIV in EndoPM, endothelial genes expression of
human and murine BMVECs was analyzed by means of
qualitative PCR and quantitative Real Time PCR and com-
pared with HMVECs.
Total RNA extraction and cDNA synthesis
Total RNA was extracted from human and mouse
BMVECs cultivated in EndoPM or EBM (as positive
control), using TRIzolW reagent (Invitrogen, Carlsbad, CA,
USA) and subsequently treated with DNase I (Ambion,
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transcribed with random hexamer primers reported in
Table 3 and Superscript III reverse transcriptase
(Invitrogen), following the manufacturer’s.
Real-time quantitative PCR
For the detection of genes related to EC biology, Real-Time
PCR was performed using the human and mouse Endothe-
lial Cell Biology RT2Profiler™ PCR Array according to man-
ufacturer’s instructions (SA Bioscience Corporation,
Frederick, MD, USA). Pathway-focused gene expression
analysis was performed with the PCR Array System and the
PCR Array Data Analysis Web Portal. Each Endothelial
Cell Biology RT2 Profiler™ PCR Array was performed on
separate cDNAs at least three times.
In vivo angiogenic assay
Mice were obtained from Charles River Italy, Calco
(LC), Italy. CD1 mice, 8-10 weeks of age, were anesthe-
tized with a solution of Tribromoethanol (AvertinW), at a
dose of 0.5 mg/g body weight. 2 × 105 human BMVECs
in 500 μL of HA hydrogel (Extracel™-X Hydrogel Kit,
Glycosan BioSystems, Salt Lake City, UT, USA) were
injected with 18-gauge needle in the abdominal quadrantTable 3 RT-PCR primer sequences and expected product size
Primers Sequences (5’-3’)
Human
CD31-f GCT GTT GGT GGA AGG AGT GC
CD31-r GAA GTT GGC TGG AGG TGC TC
vWF-f CAC TGA CAC CTG AGT GAG AC
vWF-r GTT CGT CCT GGA AGG ATC GG
Tie-2-f GGC CGC TAC CTA CTA ATGA AG
Tie-2-r CGT GAT TGA CAC TGG ACA TAA
P-gp-f GCA AAG CTG GAG AGA TCC TCA CCA
P-gp-r CAA CAT TTT CAT TTC AAC AAC TCC TGC
GAPDH-f CGG AGT CAA CGG ATT TGG TCG TAT
GAPDH-r AGC CTT CTC CAT GGT GGT GAA GAC
Mouse
CD31-f GTC ATG GCC ATG GTC GAG TA
CD31-r CTC CTC GGC GAT CTT GCT GAA
vWF-f TGT TCA TCA AAT GGT GGG CAG C
vWF-r ACA GAC GCC ATC TCC AGA TTC A
Tie-2-f GGA CAG TGC TCC AAC CAA ATG
Tie-2-r GAC GGA AAT GTT GAA AGG C
P-gp-f TGC TTA TGG ATC CC
P-gp-r TTG GTG AGG ATC TCT CCG GCT
GAPDH-f GTC GGT GTG AAC GGA TTT G
GAPDH-r TAG ACT CCA CGA CAT ACT CAG CAkeeping mice in the Trendelenburg position (head down
and legs up) to decrease the risk of bowel perforation.
Control samples were taken from sham operated mice
treated only with HA hydrogel (Glycosan). Two weeks
after transplantation, the abdominal quadrants were
removed and the isolated patches were fixed in 4%
paraformaldehyde. Serial sections of 20 μm, cut using a
vibratome, were processed by immunofluorescence. To
detect human cells, tissue sections were stained with
human nuclear antigen (hNAg). Cell engraftment in the
abdominal quadrant was evaluated by immunohisto-
logical analysis with UEA-1 and Draq5 (Table 2). Ten
fields from 20 tissues sections were randomly selected
and the images were acquired with Leica TCS SP2 AOBS
(Leica Microsystems, Heidelberg, Germany) confocal
laser scanning microscope.Statistical analysis
Each experiment was performed in triplicate, values are
expressed as mean ± SD. Comparisons of parameters
were performed using the Student's t-test. Values of
P < 0.05 (*), P < 0.01 (**) and P < 0.001 (***) were consi-
dered statistically significant.Product size (bp) Annealing T (°C)
645 49
696 60
550 50
305 60
307 58
260 55
270 62
154 60
435 55
280 55
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BMVECs growth in EndoPM and EBM
Human and mouse BMVECs cultured in EndoPM or
complete EBM were examined for their proliferation rate
by growth curve, proliferation index and survival index
(Figure 1). Results indicated that human and mouse cells
cultured in EndoPM, compared to EBM culture condition,
showed a significant increase of growth rate (Figure 1A),
proliferation (Figure 1B) and survival (Figure 1C). The
mean ± SD of repeated experiments, performed with
different cells lines, are reported in Table 1.
Cell cycle
Cell cycle was evaluated using a flow cytometer after over-
night synchronization in starvation medium. The data
showed that EndoPM facilitated the mitosis in ECs by
speeding the time of duplication. Following appropriateFigure 1 Culture characteristics of human and murine BMVECs. A) Gro
line) or complete EBM (gray lines); B) proliferation index of human and mo
DIV; C) survival index of human and mouse BMVECs cultured in EndoPM (b
profiles of human and mouse BMVEC growth in EBM (D, F) or EndoPM (E,
experiments. H) Co-culture of NHDF and BMVECs in EndoPM (black bars) o
number of CFDA-SE positive cells (NHDF) per field (Higer power field - HPFsynchronization time, starved cells were treated with
complete EndoPM or EBM medium for 5h or overnight.
In all the samples examined, the population of cells in mi-
tosis was greater after restart in EndoPM than EBM.
The results are reported in Figure 1D-G and indicate
that after overnight incubation in starvation medium the
mean % ± SD of G0/G1 of human cells was 66.4% ± 0.9;
S phase was 2.9% ± 1.2; M phase was 17.8% ± 3.3; the
mean ±SD of G0/G1 of murine cells was 53.8% ± 0.7;
S phase was 2.7% ± 1.6; M phase was 19.1% ± 2.6.
For human cells, after a further overnight restart with
complete EBM medium, the mean % ± SD of G0/G1
was 49.7% ± 9.1; S phase was 43.2% ± 6.5; M phase was
2.6% ± 0.1 (Figure 1D); while restarting with complete
EndoPM medium induced a mean % ± SD of G0/G1 of
32.9% ± 0.4; S phase of 66.3% ± 9.0; M phase of 4.5% ± 0.7
(Figure 1E). For mouse cells, after further overnight restartwth curve of human and mouse BMVECs cultured in EndoPM (black
use BMVECs cultured in EndoPM (black bars) or EBM (gray bars) at 7
lack bars) or EBM (gray bars) 12 hours after culture; D-G) cell cycle
G). Histograms are representative of one of four independent
r EBM (gray bars) after 0, 7 and 14 days of culture. Bars represent the
). * P < 0.05; **P < 0.01; ***P < 0.001.
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was 42.5% ± 10.1; S phase was 38.2% ± 7.0; M phase was
2.2% ± 0.2 (Figure 1F); while restarting with complete
EndoPM medium induced a mean ±SD of G0/G1 of
33.2% ± 0.5; S phase of 67.2% ± 7.9; M phase of 4.4% ± 0.5
(Figure 1G).
These data suggest that EndoPM induced a G1 phase de-
crease compared with complete EBM, and was accompan-
ied by a significant increase of cells in the S phase and a
slight increase of M phase cells (P < 0.05 for both cells
type). Figure 1 (D-G) is representative of repeated experi-
ments performed with different cells lines.Co-culture of BMVECs and NHDF
To test the capability of EndoPM on the inhibition
of a contaminant cell population, (e.g. fibroblasts), co-
cultures of BMVECs and normal human dermal fibro-
blasts (NHDF) were produced by pooling both cell types
at the ratio BMVECS:NHDF = 3:1. 24 h after seeding the
mean densities of human BMVECs and NHDF were
approximately equal in co-culture (Figure 1H). After
24 h of co-culture, the number of NHDF cells was
stable. NHDF cells decreased after 7 and 14 days of
culture. During co-culture condition, a significant re-
duction of NHDF density under the influence of
EndoPM was detected compared with complete EBM
culture. The reduction of NHDF cells after culture in
EndoPM was approximately 95% after 14 days of cul-
ture (Figure 1H).Expression of endothelial cell phenotype and morphology
of EndoPM cultured cells
BMVECs cultured in EndoPM showed phenotypical
and morphological stability during 12 months of cul-
ture and no evidence of overgrowth by contaminating
cells was found. As seen by phase-contrast microscopy,
EndoPM cultured BMVECs formed a monolayer with a
cobblestone-like morphology composed of density-
inhibited cells, which were not senescent, but still prolifer-
ative when split (Figure 2A).
In order to confirm the endothelial phenotype of
BMVECs, several EC markers were examined by immu-
nocytochemistry and FACS analysis.
Immunofluorescence analysis revealed strong posi-
tivity for CD31 (Figure 2B) and von Willebrand Fac-
tor (vWF) (Figure 2C). In addition, FACS analysis by
multiple surface epitopes showed high expression of
CD31 (human 99.42% ± 0.96; mouse 84.88% ± 16.48),
CD146 (human 97.42% ± 4.3; mouse 84.19% ± 11.93),
human CD105 (97.96% ± 3), mouse CD34 (82.89% ±
17.64), Ulex europaeus agglutinin-1 (UEA-1) (99.9% ±
0.07) and mouse Tie-2 (84.37% ± 3.48) (Figure 2D).Functional assays for BMVECs
To determine whether EndoPM cultured BMVECs were
able to show angiogenic function, 6 × 104 cells were
plated on Matrigel and the cultures were examined for
capillary tube-like structure formation. BMVECs exhi-
bited an angiogenic response within 5-7 h and migrated
from the evenly distributed monolayer of cells to form
net-like, capillary tube-like structures with open areas
with no cells around (Figure 2E). This was observed for
every sample of human and murine BMVECs, with no
major differences observed.
Using immunofluorescence staining, in vitro endothe-
lial functionality was demonstrated on BMVECs by
evaluating: uptake of Dil labeled acetylated low-density
lipoprotein (Dil-Ac-LDL) (Figure 2F), expression of Glu-
cose transporter 1 (GLUT-1) (Figure 2G) and positivity
for endothelial nitric oxide synthase (eNOS) (Figure 2H).
A similar uptake of Dil-Ac-LDL (intense punctate stain-
ing in the perinuclear region), expression of GLUT-1
and eNOS were detected in human and murine popula-
tion cultured in complete EBM condition. Overall, these
observations further indicate that human and murine
BMVECs cultured in EndoPM retain key phenotypic
features of ECs, despite serial time-passaging and culture
in vitro.
In addition, cells resulted positive for functional markers
of cellular junctions as adherent junctions VE-Cadherin
and β-catenin and tight junction Claudin-5, after 5 days
culture in EndoPM medium without Hormone mix
(Figure 3A, B, C).
Vascular permeability assay
Macromolecules (FITC-dextran) are used to examine
the permeability of the endothelium monolayer formed
after isolation of BMVECs by means of the described
protocol. Although the readout of this assay is not suffi-
cient to draw conclusions, it is clear that cells cultured
in EndoPM medium and then plated in appropriate
transwells strongly reduce macromolecules permeability
throughout the barrier over 12 hours, as functional test
of vascular permeability (Figure 3D).
BMVEC expression of endothelial genes
Using RT-PCR assay, molecular analysis of EC biology
was performed on BMVECs to compare gene expression
between our isolated EndoPM human and mouse
BMVECs and EC line cultured in complete EBM. The
identified genes were classified into pro-angiogenic and
adhesion molecules genes. BMVECs and HMVECs
showed similar expression levels of the most represen-
tative angiogenic genes: vWF, KDR, FLT-1, VEGF-A,
PECAM-1. In addition, an overexpression of pro-
angiogenic genes such as angiopoietin (ANGPT1 +4.14
fold increase), AGTR1 (+3.28 fold increase), SELPLG
Figure 2 Characterization and functional features of human and murine BMVECs. (A) Phase contrast micrographs of confluent monolayers
of human (left image) and murine (right image) BMVECs. BMVECs present the typical “cobblestone appearance”. Scale bar, 100 μm and 200 μm
for human BMVECs and murine BMVECs. B) Human (left image) and murine (right image) BMVECs showed a clear cytoplasmic staining for CD31.
Scale bar, 50 μm. C) Human (left image) and murine (right image) cells displayed an intense positive immunofluorescence for vWf. Scale bar,
50 μm. D) Flow cytometric analysis of BMVECs. Human BMVECs resulted positive (gray histograms) for CD31 (left graph), CD105, CD146
(left gaph), UEA-1 staining; murine BMVECs resulted positive for CD31 (right graph), CD34, CD146 (right graph) and Tie-2 staining. White
histograms represent the isotype controls of each antibody. E) Capillary tube-like structure produced by human (left image) and murine
(right image) BMVECs, 7 h after plating onto Matrigel. Scale bar, 100 μm. F) LDL-uptake assay on human (left image) and murine (right image)
BMVECs. Scale bar, 50 μm. G) Human (left image) and murine (right image) BMVECs were labelled for GLUT-1. Scale bar, 50 μm.
H) Immunofluorescence for eNOS in human (left image) and murine (right image) BMVECs. Scale bar, 50 μm. All nuclei were counterstained with
DAPI (blue). One representative of three independent experiments performed in blind is shown for each figure.
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was found. Adhesion molecules genes up-regulated
included ITGAV (+41.64 fold increase), ICAM1 (+8.05
fold increase), VCAM1 (+2.60 fold increase) and TNFAIP3
(+5.77 fold increase) (Figure 4A). Furthermore, CD31,
vWF, Tie-2 and P-glycoprotein (P-gp) transcripts, analyzed
by qualitative PCR, were detected in all cultures tested
(Figure 4B).
In vivo angiogenic assay
In order to evaluate whether EndoPM cultured human
BMVECs could integrate into mouse tissue and if they
had the capability to construct new blood vessels, we
opted for a xenograft model in the CD1 mouse strain.
2 × 105 cells were engrafted in the abdominal quadrant
of CD1 mouse. We analyzed 15 mice divided into two
groups: group 1 (n = 10) underwent transplantation with
EndoPM cultured human BMVECs embedded in hydro-
gel, group 2 (n = 5) underwent injection of hydrogel
without BMVECs. Two weeks after transplantation,
macroscopic differences were noticed in mice that
received BMVECs in hydrogel (Figure 4C) compared
with the mice that received only hydrogel (Figure 4D).
Histological examination with human specific antibodies
showed that implanted cells were immunoreactive forFigure 3 Tight junctions markers and Vascular Permeability Assay of
medium, then incubated 5 days in EndoPM medium without Hormone Mix. I
endothelial cell monolayers for VE-cadherin (A), Claudin-5 (B), β-catenin (C). N
permeability of the endothelium monolayer formed after isolation of BMVECs
and then plated in appropriate transwells strongly reduce macromolecules pe
vascular permeability. All the experiments were repeated at passages n. 5, 10UEA-1 and for double staining with Draq5 and anti-
human nuclei (hNAg), thus confirming the presence of
human cells expressing the endothelial marker in many
sections (Figure 4E). The specificity of the staining was
established by the absence of human UEA-1 and anti
human nuclei positive cells in the patch of mice that did
not receive endothelial cells (Figure 4F).
Discussion
Several recent studies have highlighted the importance
of research on the brain ECs that form the blood brain
barrier (BBB) for the study of the physiology and
pharmacology of cerebrovascular diseases [20-22].
In the present study, we describe a newly formulated
medium for the culture of brain-derived human and
mouse ECs (BMVECs), based on our studies in the isola-
tion, culture and characterization of ECs from different
human organs [23,24]. Such invention is suitable for the
generation of an in vitro model in the field of cere-
brovascular diseases’ investigation. It guaranties the
isolation and maintenance of BMVECs with high purity,
in any laboratory and with minimal equipment and
accessories.
In contrast with other methods described in the litera-
ture [11,18,21,25], our technique is simply based on theBMVECs. Murine BMVECs were isolated and cultured in EndoPM
mmunofluorescent staining of confluent human brain microvascular
uclei were stained with DAPI. Scale bar = 50 μm. D) FITC-dextran
by means of the described protocol. Cells cultured in EndoPM medium
rmeability throughout the barrier over 12 hours, as functional test of
and 15 without significant differences in the obtained results.
Figure 4 Gene expression profile and in vivo engraftment. A) RT2 profiler of human BMVECs cultured in EndoPM in comparison with cells
cultivated in complete EBM; B) Endothelial gene expression of human and murine BMVECs analyzed by means of qualitative PCR. C-D) in vivo
engraftment: photographs of the abdominal quadrant of CD1 mice that received C) or did not receive D) human BMVECs cultured in EndoPM;
E) Grafted human BMVECs abdominal quadrant is used for immunostaining. Cells were immunoreactive for UEA-1 (green) 2 weeks after
transplantation. The presence of live human ECs was confirmed by Draq5 (red) positivity and anti-human nuclei (hNAg, blue) positivity. The
lower-right image represents the merge between UEA-1, Draq5 and anti-human nuclei. Scale bar, 50 μm. F) The control abdominal quadrant that
received vehicle only resulted UEA-1 negative (upper-left image) and Draq5 (red) positive. DAPI was used for nuclear staining. The lower-right
image represents the merge between UEA-1, Draq5 and DAPI. Scale bar, 20 μm.
Navone et al. Vascular Cell 2013, 5:10 Page 10 of 12
http://www.vascularcell.com/content/5/1/10formulation of a low-serum medium called “Endothelial
Proliferation Medium” (EndoPM, patent number MI2011A
000201), with the addition of a high concentration of
growth factors, but without immunomagnetic selections or
gene manipulations. In order to show the efficacy of
EndoPM, we considered whether BMVECs isolated and
maintained in the newly formulated medium demonstrated
both phenotypical and functional endothelial cell markers.
EndoPM medium had a significant effect on inducing the
selection and proliferation of BMVECs when compared
with commercially available EBM medium supplemented
with growth factors kit. The cell population cultured in
EndoPM formed typical cobblestone patterns consistent
with their EC lineage [6]. BMVECs, cultured for more than
60 DIV in EndoPM, continuously maintained endothelial
features during the course of this study. Moreover,
BMVECs could be cryopreserved, maintaining high viabi-
lity and showing expression of characteristic markers after
thawing (data not shown).
One of the most important features of this technique is
the efficiency of purification from fibroblast contaminationin our BMVECs culture, as demonstrated in our laboratory
by co-culture assays.
This significant effect of EndoPM on BMVECs was
confirmed by cell cycle analysis. Data show that cells
cultured in EndoPM were able to overcome the G1
restriction checkpoint level more easily than when
cultured in complete EBM medium. The G1 phase check-
point (the restriction point) is controlled mainly by the
action of the CKI-p16 (CDK inhibitor p16), a protein that
inhibits CDK4/6, ensuring no more interaction with cyclin
D1. Its levels are maintained through G1 phase and are
required for the initiation of S phase, at which time cyclin
D1 levels are automatically reduced to low levels. In this
way, cyclin D1 is proposed to serve as an active switch in
the regulation of continued cell cycle progression [17].
Analysis on the expression level of cyclins in EBM and
EndoPM endothelial cultures are still ongoing.
Human and murine BMVECs cultured in EndoPM
expressed all the markers typically used to confirm
endothelial lineage [21], such as CD31 and vWF, and
were accompanied by rapid formation of capillary-like
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[27], specific transporters (i.e., GLUT-1 [28]) and P-gp
[29,30] expression. Moreover BMVECs were able to
express markers of the junctional architecture such as
Ve-cadherin, β-catenin and Claudin-5, demonstrating
their in vitro capability to show typical features of BBB.
In addition, BMVECs, in confluence culture condition,
inhibit macromolecules transcytosis as demonstrated by
vascular permeability assay [31].
In order to identify transcriptional differences between
cells cultured under these two expansion-media con-
ditions, a combined panel for endothelial phenotype
related gene expression profile [32] analysis was carried
out by using Real Time PCR. Our data revealed higher
expression of genes related to the angiogenetic pathway
on EndoPM cultured BMVECs, such as ANGPT1,
AGTR1, SELPLG and ADAM17. Gene expression ana-
lysis and endothelial markers expression, also after
engraftment in CD1 mouse strain, provided further evi-
dence of endothelial origin of our BMVECs isolated and
expanded with EndoPM.
We also observed additional beneficial features of
EndoPM particularly higher and longer-term prolifera-
tion rates of BMVECs without concerns regarding scale
and variation. Moreover, phenotypical/functional charac-
teristics of cells were not altered by or after freezing/
thawing storage techniques.Conclusion
Our results suggest that BMVECs cultivated with our new
technique retain numerous endothelial characteristics,
and we believe that these cells will provide a promising
tool for use in the development of in vitro models that
simulate cerebrovascular diseases as well BBB pathologies.
Our invention permits studies on human and murine
BMVECs with extended lifetime, good viability and
purity without alterations to their endothelial features.
Cell lines cultured with our method could be a useful
model for studying the biology of cerebral endothelium
in the context of neuro-inflammatory, neurodegenerative
or infectious diseases and for large-scale screening of
CNS drug candidates.
It should be noted that we have just begun application
of BMVECs isolated with our method for the studies in
cerebrovascular diseases area, and it is expected that
further efforts to strengthen our knowledge of their func-
tional properties will add significant value to the cells,
which are known to be essential to the establishment of
in vitro cerebrovascular diseases and BBB models.
Here we demonstrate improved efficiencies for
BMVECs isolated specifically from human and mouse
brain biopsies. In the future these conditions should be in-
vestigated for the isolation of ECs from other bodydistricts, such as adipose, skin or bone marrow cell
populations.
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